KRAS and GNAS mutations are both associated with poor survival in patients with CRC and PMP [7,37,38], and treatments that exhibit efficacy in models with these genomic aberrations could potentially have an impact on a large patient group. This evidence concerns the gene KRAS and colorectal carcinoma.